Walleye Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Walleye Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$140K	Buy	6,400 +1,000	+19%	+$20.8K	﹤0.01%	3706
2026 Q1	$126K	Sell	5,400 -8,300	-61%	-$180K	﹤0.01%	3572
2025 Q4	$288K	Sell	13,700 -5,100	-27%	-$89K	﹤0.01%	3346
2025 Q3	$289K	Sell	18,800 -10,800	-36%	-$141K	﹤0.01%	3036
2025 Q2	$277K	Buy	+29,600	New	+$326K	﹤0.01%	3110
2024 Q4	–	Sell	-1,000	Closed	-$19.3K	–	5511
2024 Q3	$19.3K	Buy	+1,000	New	+$20.7K	﹤0.01%	4820
2024 Q1	–	Sell	-4,100	Closed	-$88.6K	–	5863
2023 Q4	$88.6K	Buy	+4,100	New	+$63K	﹤0.01%	4100

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Walleye Capital's SNDX Position: Q2 2026 in Review

Walleye Capital reduced its Syndax Pharmaceuticals (SNDX) stake by 99% in Q2 2026, selling an estimated $7.89M and leaving 5,636 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #3771.

Walleye Capital first reported a position in SNDX in Q4 2022 and has held it in 12 quarters since. The position peaked at $11.5M in Q1 2023. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Walleye Capital held 5,636 shares of Syndax Pharmaceuticals worth $123K as of Q2 2026.
Walleye Capital sold 379,337 Syndax Pharmaceuticals shares in Q2 2026, an estimated $7.89M.
Syndax Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3771 holding.
Walleye Capital first reported a position in Syndax Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
Walleye Capital's Syndax Pharmaceuticals position peaked at $11.5M in Q1 2023.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.